After reading your response, I have to chuckle at Kirk's view of Palifosfamide as a "rounding error".
I have to take Kirk's comments with a healhty degree of skepticism but I would love to be proven wrong. I'm long ZIOP for what they had in their pipeline prior to Intrexon so I view anything of value coming from Intrexon as a bonus.
Aria: I know you were a skeptic due to Mrk's lack of pounding the table on Rida after the Succeed results. Are you looking to the follow through data (good or bad) as a potential entry?
I won't be adding any more biotechs any time soon unless one of my current holdings moves significantly for me. I have no available cash to invest. But, I'm at the point now where I want to get additional clarification on the Rida results before I would do anything with ARIA. If there's some kind of negative development with Rida and the stock sells off to any material degree, I'd be interested given ponatinib.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.